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Abstract
Background/Aims: Renal transplant recipients are exposed to immunosuppressive treatment 
which may increase the risk for developing malignancies. Limited data exists concerning the 
occurrence of multiple primary malignancies (MPM) in renal transplant patients. Methods: All 
the patients who received a renal allograft at our institution from 1973 to 2017 were included 
in this investigation. Data from patients with more MPM were obtained from the charts and 
medical records. Malignancies were categorized as synchronous if the interval between 
occurrences was less than or equal to 6 months and metachronous if the interval was more 
than 6 months. Results: Out of the 1884 patients who received a renal allograft, 164 (8.7%) 
developed a malignant tumor. Twenty-two patients (13.4%; 6 females, 16 males) developed 
MPM, 7 synchronous (31.8%) and 15 metachronous types (68.2%). The most common initial 
primary tumors were skin cancers (8) and kidney cancers (3). Furthermore, skin cancers were 
the most common second primary malignancies (9). Log-rank analysis revealed significantly 
better survival in the synchronous group (113.3 months) than in the metachronous group 
(24.6 months) (p=0.04). Conclusion: MPM are more frequent in renal transplant recipients 
than in the general population. It is associated with a high mortality rate, especially in the 
metachronous group. An increased awareness and frequent screening tests are necessary 
when managing this condition.
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IntroductionMultiple primary malignancies (MPM) are a prevalent phenomenon that are usually 
defined as primary malignant tumors of different histological origins in one person [1]. 
They are defined by the following criteria: (1) every tumor has definite features of malignant 
change, (2) every tumor is anatomically separate, (3) the second tumor cannot be a metastatic 
lesion or due to recurrence of the first tumor, and (4) the following primary malignancies 
have to be present in either the same or different organs [2]. Multiple primary malignancies 
may be classified as synchronous or metachronous. The synchronous type is defined as 
malignancies that are observed at the same time or within 6 months of each other, and 
malignancies that develop after 6-months of one another are considered as metachronous 
MPM [3]. The etiology of this occurrence has not been completely elucidated. It is believed 
to involve the patient’s exposure to known carcinogens like chemotherapy and radiotherapy 
during the treatment of the initial tumor, genomic structural variations that can increase a 
patient’s tumorigenic susceptibility and the functional status of a patient’s immune system 
[4].
Current literature contains limited data concerning MPM in renal transplant recipients. 
In this retrospective study, we analyzed the occurrence of MPM at our renal transplant 
program over a 44-year study period.
Materials and Methods
This was a retrospective cohort study including a series of 1884 consecutive renal transplant patients 
who received a renal allograft at the University hospital centre Zagreb from 1973 to 2017. Patients were 
regularly followed up every three months at the outpatient clinic. Immunosuppression has changed with 
time. Universal induction with basiliximab was introduced in 2006, and for sensitized patients we used 
polyclonal antibodies. Initial maintenance immunosuppressive therapy was usually done by utilizing a 
triple drug regimen containing cyclosporine (640 patients) or tacrolimus (1244 patients), azathioprine 
(482 patients) or mycophenolate (1402 patients) and steroids. From 1999 onward we generally used 
mycophenolate instead of azathioprine, and from 2007 onward tacrolimus instead of cyclosporine. After 
January 2008, patients with a history of malignancy or with post-transplant malignancy received an mTOR 
inhibitor instead of a calcineurin inhibitor if they had no contraindications to the medication (proteinuria, 
acute rejection, side-effects, or donor-specific antibodies) (92 patients). Acute rejection was recorded in 
296 patients (15.7 %). Episodes of acute rejection were treated with steroid pulses (296 patients), while 
78 patients also underwent plasma exchange for treatment of humoral rejection, and 4 received ATG for 
treatment of steroid resistant acute rejection.
Patients were diagnosed based on medical history, physical examination, appropriate radiographic 
and/or endoscopic examinations, and pathological results. The time interval to differentiate between 
synchronous or metachronous types required 6 months. The inclusion criteria of patients in this study 
were the presence of at least two neoplastic locations confirmed by histopathological examination and 
tumors with distinct histopathology in different locations. Patients were excluded from the investigation 
if they didn’t have a clear histopathological confirmation of each tumor, if the second tumor was suspected 
to be a metastasis of the first location, as well as patients with the first malignancy being diagnosed 
before transplantation and the second malignancy being diagnosed after the transplantation. Patient age 
at the time of each tumor diagnosis, gender, site of origin, synchronous or metachronous appearance, 
immunosuppressive protocol, treatment regimen and outcome have been recorded.
Statistical analysis was performed using Stata/SE 11.2 for Windows (StataCorp LP, USA). Differences 
between these two groups were analyzed by using Fisher’s exact test or the Mann Whitney U test at the level 
of significance P < 0.05, with Kaplan-Meier analysis for survival.
The study protocol was approved by the Institutional Review Board and conformed to the ethical 
guidelines of the Declaration of Helsinki.
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Results
Patients’ characteristics
Over the observed period, 1884 patients received a renal allograft (1114 male), with an 
average age at the transplantation of 55 years (range 18 to 77 years), and median follow-
up time of 8 years. There were 673 transplantations from 1973 to 2007 and 1211 from 
2007 to 2017, this abrupt increase can be attributed to Croatia entering the Eurotransplant 
organization during this time.
There were 164 patients who developed a malignancy, and 22 who had MPM. There was 
a male predominance (16 male vs. 6 female) and the median age at the time of diagnosis of 
the first primary malignancy was 61 (range 39-77) years. Primary kidney diseases included 
glomerulonephritis (7), endemic nephropathy (3), pyelonephritis (3), nephroangiosclerosis 
(2), diabetic nephropathy (1), polycystic kidney disease (1) and an idiopathic cause of kidney 
failure in 4 of the patients. The median time of dialysis vintage was 5.14 years (range 0.5-12 
years). The time frame between transplantation, development of the first tumor and of the 
second tumor is shown in Table 1.
Four patients had two renal transplantations. Two patients had a history of malignancy 
before transplantation (one colon cancer and one basal cell carcinoma). Six patients were 
smokers.  The immunosuppressive protocol included induction in 12 patients (basiliximab 
in 10 and antithymocyte globulin in only 
2 patients). Sixteen patients received 
cyclosporine and 6 patients, tacrolimus. 
Azathioprine was used in 7, mycophenolate 
in 14 and everolimus in one patient. Two patients developed acute cellular rejection 
and were treated with steroid pulses.
Significantly more patients treated with 
cyclosporine or azathioprine developed 
MPM compared to patients treated with 
other immunosuppressive drugs (Fisher 
exact test, p=0.007) (Table 2).Three patients had chronic hepatitis 
C virus infections, and two had CMV 
infection. No other viral infections were 
recorded.
Synchronous and metachronous 
malignancies
Seven patients (32%) developed 
synchronous and 15 (68%) metachronous 
MPM. The mean time from renal transplantation until the diagnosis 
of MPM was 10 years (range 2-20) 
for the synchronous and 2 years 
(range 1-25) for the metachronous 
group (Mann-Whitney p=0.02). 
Patients’ characteristics based on 
the time of cancer occurrence are 
presented in Table 3.
There was no difference 
between the synchronous and the metachronous group regarding the 
type of primary kidney disease.
Table 1. Time frame between transplantation and 
diagnosis of the malignancies. IQR; interquartile 
range; Tx, transplantation
 
Time (years) Median (IQR) Range From Tx until the 1st tumor  4 (1 – 11) 1 – 25 From the 1st until the 2nd tumor 1,5 (0,3 – 3) 0 – 11 From Tx until the 2nd tumor  7,5 (4 – 13) 2 – 26   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Patients’ characteristics based on the time of cancer 
occurrence are presented in Table 1. MPM, multiple primary 
malignancies; IQR, interquartile range). †Mann Whitney U test
 
 
Parameter Type of MPM P* Synchronous (n=7) Metachronous (n=15) Total (n=22) Gender [n(%)]     Male 4 (57) 11 (73) 15 (68) 0,63 Female 3 (43) 4 (27) 7 (32) Age [years] [Median (IQR)] 54 (51 – 74) 75 (67 – 80) 73 (56 – 78) 0,02† Dialysis vintage [years]  [Median (IQR)] 6 (1 – 10) 4 (2 – 7) 4,5 (2 – 9) 0,55†  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Development of multiple primary malignancies 
depending on the use of immunosuppressive drugs. 
Fisher exact test
 
Variable Number (%) of patients P* With MPM Without MPM Total Cyclosporine 16 (36,4) 624 (16,8) 640 (17) 
0,007 Tacrolimus 6 (13,6) 1146 (30,8) 1152 (30,6) Everolimus 1 (2,3) 91 (2,4) 92 (2,4) Azathioprine 7 (15,9) 475 (12,8) 482 (12,8) Mycophenolate  14 (31,8) 1388 (37,3) 1402 (37,2)   
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Localization and immunosuppression at the time of occurrence and treatment of the first 
primary malignancy are presented in Table 4. The most common first primary malignancy 
was basal cell carcinoma in 27% of cases.
Localization and immunosuppression at the time of occurrence and treatment of the 
primary malignancy is presented in Table 5. The most common second primary carcinoma 
was squamous cell carcinoma of the skin, occurring in 23% of patients.
Tumor correlations for synchronous tumors were: colon-colon, kidney-colon, ovary-
colon, urinary bladder-ovary, kidney-kidney, skin SCC- skin BCC, skin BCC- skin SCC.
Tumor correlations for metachronous tumors were: thyroid-lung, BCC-SCC (2 patients), 
SCC-BCC (2 patients), Merkel cell skin cancer-SCC, prostate-urinary bladder, urinary bladder-
kidney, kidney-urinary bladder, prostate-SCC, BCC-plasmocytoma, BCC-glyoblastoma, 
thyroid-melanoma, breast-BCC, thyroid-breast.
Log-rank analysis revealed significantly better survival in the synchronous group (113, 
3 months, 95% CI 79, 3 – 147, 2) than in the metachronous group (24, 6 months, 95% CI 
14.7-34.5) (p=0.04) (Fig. 1).
Discussion
The frequency of MPM ranges between 2.4% and 20% based on the definition in 
literature and is increasing with longer patient follow-up [5]. The incidence of MPM has 
increased significantly due to improvements in diagnostic methods and with the discovery 
of new treatments, which allows for more patients to survive long enough to develop 
additional primary tumors [6]. Attributing factors involve improved screening, advances in diagnostic testing, more sophisticated anticancer treatment regimens, an improved 
overall surveillance of patients with cancer and better nutritional support. Cancer survivors 
may be more susceptible to developing second primary malignancies due to many factors 
which include a genetic predisposition towards cancer, environmental exposures, specific 
Table 5. Localization and immunosuppression at 
the time of occurrence and treatment of the second 
primary malignancy. BCC, basal cell carcinoma; 
SCC, squamous cell carcinoma; C, cyclosporine; 
T, tacrolimus; S, steroid; M, mycophenolate; A, 
azathioprine. *Fisher exact test
 
 
Secondary tumor Type P* Synchronous (n=7) Metachronous (n=15) Tumor 2 [n(%)]    Kidney 1 (14) 1 (7) 
0,27 
BCC 1 (14) 3 (20) Colon 3 (43) 0 Urinary bladder 0 2 (13) Ovary 1 (14) 0 SCC 1 (14) 4 (27) Breast 0 1 (7) Lung 0 1 (7) Plasmocytoma 0 1 (6,7) Glyoblastoma 0 1 (6,7) Melanoma 0 1 (6,7) Immunosuppression 2 [n(%)]    C+M+S 1 (17) 0 0,26 mTOR + M + S 3 (50) 11 (73) T + M + S 2 (33) 2 (13) C + S 0 2 (13) Treatment 2 [n(%)]    Operative 5 (71) 12 (80) 0,07 Operative + mTOR 2 (29) 0 Palliative  0 3 (20)  
Table 4. Localization and immunosuppression at 
the time of occurrence and treatment of the first 
primary malignancy. BCC, basal cell carcinoma; 
SCC, squamous cell carcinoma; C, cyclosporine; 
T, tacrolimus; S, steroid; M, mycophenolate; A, 
azathioprine. *Fisher exact test
 
 
Primary malignancy Type P* Synchronous (n=7) Metachronous (n=15) First tumor [n(%)]    Kidney adenocarcinoma 2 (29) 1 (7) 
0,39 
BCC 2 (29) 4 (27) Colon cancer 1 (14) 0 Urinary bladder 1 (14) 1 (7) Thyroid 0 3 (20) Prostatic gland 0 2 (13) Ovarian 1 (14) 0 SCC 0 2 (13) Merkel cell cancer 0 1 (6,7) Breast 0 1 (6,7) Immunosuppression 1 [n(%)]    C+M+S 3 (43) 6 (40) >0,99 C+A+S 2 (29) 5 (33) T+M+S 2 (29) 3 (20) mTOR + T + S 0 1 (7) Treatment 1 [n(%)]    Operative 6 (86) 8 (53) 
0,51 Operative + mTOR 1 (14) 1 (7) Operative+ irradiation 0 4 (27) Operative + radioactive iodine 0 1 (7) Operative + tamoxifen 0 1 (7)  
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Fig. 1. Kaplan-Meier survival analysis comparing survival of 
patients with synchronous and metachronous multiple primary 
malignancies.
characteristics of some 
tumors, and adverse effects of 
treatment with chemotherapy 
and/or radiotherapy. Increased 
risk for MPM was found to 
correlate with family history, race, younger age at the time 
of diagnosis, a lower tumor 
stage and with indolent cancer 
behavior which enables 
prolonged survival [7]. 
Although there are numerous reports addressing the clinical 
features of MPM in the general population, literature on this topic in the renal transplant 
population is scarce.
Therefore, this 
retrospective study was designed to evaluate the clinical 
characteristics and outcomes of MPM involving renal transplant patients. The incidence of 
MPM in our study was 1.16% among all renal transplant recipients and 13.4% among renal 
transplant patients with malignancies. Of the 22 cases (6 females, 16 males) diagnosed with 
MPM, 7 were synchronous (31.8%) and 15 were the metachronous variant (68.2%). In the 
study of Bisof et al. from our institution, the incidence of MPM in the general population of 
oncology patients was 2.4%. Among 103 patients, 83 cases were metachronous (80.5%), 
and 20 cases (19.5%) were synchronous malignancies. The frequency was higher in females 
than males. The most common tumor combinations in males were: prostate cancer-digestive system malignancy (especially colorectal cancer) and vice versa, and hematological malignant 
tumors-digestive system malignancy. While in women the most frequent were: breast cancer-
cancer of contralateral breast and hematological malignant tumors (especially lymphoma 
non Hodgkin)-breast cancer [8]. In the transplanted population from our institution, the most 
common tumor combinations were different skin malignancies. Based on this comparison, it 
is obvious that the incidence of MPM was higher in renal transplant recipients (13.4%) than 
in the general population (2.4%). Additionally, in the general population MPM was more 
common in female and renal transplant populations than in male patients, with a diverse 
spectrum of localizations.
Our results are in contrast with previously reported data. Santangelo et al. did not find a 
higher risk for development of MPMs as compared to the corresponding general population. 
Their explanation is based on the fact that kidney-transplanted patients probably die before 
a new “second primary malignancy” appears or due to interruptions of immunosuppressive 
therapy, thus limiting the exposure to oncogenic effects of such drugs over time while they 
return to dialysis. In their practice, it was hard to find transplanted patients who survived the 
first malignancy and then continued immunosuppressive treatment long enough to develop 
a second primary cancer as a consequence of iatrogenic immune deficiency [9]. Taioli et al. 
investigated the incidence of a MPM in 7, 636 patients who underwent a kidney, liver, lung 
or heart transplant between 1970 and 2004. They did not find an increased risk of MPM in 
transplanted patients with a previous malignancy [10]. To our knowledge, only these two 
reports have specifically examined the incidence of MPMs in transplanted patients. Tessari 
et al. reported an increased risk for the development of primary and second cancers in the 
renal transplant population, with the type of second cancer being dependent on the type 
of the primary. Patients with nonmelanoma skin cancer developed a second nonmelanoma 
skin cancer, and patients with nonskin cancer developed a second nonskin cancer [11]. Our 
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results demonstrate that all types of tumors may occur in various possible combinations, 
and are not limited to skin or nonskin localizations.
Our results may differ from the results of Santangelo [9] and Taioli [10] for the following 
reasons: after malignancy diagnosis our patients are allowed (after detailed information) 
to choose between three different approaches: cessation of immunosuppression and 
graftectomy, minimization of existent immunosuppressive therapy or switching to an mTOR 
based immunosuppressive regimen (instead of the calcineurin inhibitor). So far, none of the 
patients have decided to stop immunosuppression and return to dialysis. Additionally, an 
exponential increase in the number of transplantations performed in Croatia has enabled 
transplantations for very old patients who are prone to develop malignancies. Based on a 
combination of factors (improved diagnosis, improved treatment, demographics), it may be 
expected that this aging transplant population will lead to an increased prevalence of MPM.
Our study observed a higher number of the metachronous subtype versus synchronous 
malignancies.  This contrasts the results of Santangelo et al. but is in agreement with a 
large observational study [9, 12]. While our results show a significant mortality advantage 
of synchronous over metachronous malignancies, the observational study revealed the 
opposite with a median survival time that was greater for the metachronous subtype, 96 
months from diagnosis compared to 12 months.  Their study showed that an interval time of 
less than 60 months was a positive prognostic factor for patients with metachronous cancer 
[12].
In contrast to the healthy population, squamous cell carcinoma of the skin is more 
common than basal cell carcinoma in immunosuppressed patients.  However the limited 
number of skin cancer occurrences in this study limits the support of this conclusion in renal 
transplant recipients with MPM [9].
Survival of patients with MPM in the general population depends on the cancer type 
and stage at diagnosis, but also on comorbidities, behavioral and genetic factors. In renal 
transplant recipients, allograft dysfunction can cause lymphocyte attenuation and the 
immunosuppression may affect survival by altering the immune response.  This along with 
immunosuppressive therapy can have direct oncogenic effects by inhibiting apoptosis, 
increasing the expression of transforming growth factor-beta (TGF-beta) and vascular 
endothelial growth factor (VEGF) (cyclosporine and tacrolimus), inducing DNA damage 
and negatively influencing DNA repair (azathioprine), or by promoting genetic mutations 
(polyclonal antibodies). On the contrary, it has been shown that some tumor types may 
regress with the use of mTOR inhibitors [13] and mycophenolate [14]. In our cohort, we did 
not find any difference between the type of immunosuppression and time-frame of cancer 
occurrence, or with survival. However, a significantly higher proportion of patients treated 
with cyclosporine or with azathioprine developed MPM than those who received tacrolimus, 
mycophenolate or everolimus. The small number of patients limits further statistical analysis 
to reveal the role of prolonged exposure to immunosuppression in general (which is present 
in patients who receive cyclosporine or/and azathioprine).
Renal transplant patients who are smokers, alcoholics, have a hereditary predisposition 
or with a primary malignancy before transplantation have an increased risk for the 
development of MPM. Additionally, the number of octogenarians receiving allografts is 
increasing. All these factors may contribute to the problem of MPM in the renal transplant 
population. As a preventive strategy, renal transplant recipients should be encouraged to 
stop the use of alcohol and tobacco, exercise regularly and adopt a healthy diet in order 
to regulate body weight. Regular dermatological examinations are mandatory. Studies have 
shown that the immunocompromised state of dialysis patients leads to a significant increase 
in malignancies due to uremic and dialysis prompted lymphocyte dysfunction, and several 
metabolic misbalances.  However, there has not been a comprehensive study of MPM in this 
population [15].
There are some limitations of our study. During the observed period, the changing 
landscape of recipient demographics and comorbidities may influence our results. For 
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different reasons many patients have changed their initial immunosuppressive protocol 
during the post-transplant follow-up. The small number of patients on T cell depleting agents 
and with viral infections prevent an analysis about their possible roles in oncogenesis, which 
are well known drivers of post-transplant neoplasia [15].
Conclusion
Multiple primary malignancies were not uncommon in our cohort and occurred 
synchronously or metachronously. With regular follow-up of patients with a primary 
malignancy, most of the metachronous second primary malignancies could be detected at 
an earlier stage.
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